Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

Study Identifier:
ECU-DGF-201
ClinicalTrials.gov Identifier:
NCT02145182
EudraCT Identifier:
2013-004650-25
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Eculizumab
  • Drug: Placebo
Date
Aug 2014 - Nov 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Eculizumab
  • Drug: Placebo
Date
Aug 2014 - Nov 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.

Trial Locations

Location
Status
Location
Birmingham, Alabama, United States, 35294
Status
N/A
Location
Phoenix, Arizona, United States, 85054
Status
N/A
Location
Los Angeles, California, United States, 90024
Status
N/A
Location
Palo Alto, California, United States, 94304
Status
N/A
Location
San Francisco, California, United States, 94115
Status
N/A
Location
San Francisco, California, United States, 94143
Status
N/A